# Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48)

> **NCT02575638** · PHASE1 · UNKNOWN · sponsor: **Cao Pharmaceuticals Inc.** · enrollment: 65 (estimated)

## Conditions studied

- Malignant Lymphoma of Extranodal and/or Solid Organ Site
- Solid Tumor

## Interventions

- **DRUG:** CZ48

## Key facts

- **NCT ID:** NCT02575638
- **Lead sponsor:** Cao Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-07
- **Primary completion:** 2019-10-01
- **Final completion:** 2020-02-01
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2019-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02575638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02575638, "Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02575638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*